title: Response to Suissa and Azoulay. The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. Diabetes Care 2014;37:1360-1366.
authors.affiliation: Department of Oncology, Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, Ontario, Canada louise.bordeleau@jcc.hhsc.ca.
authors.forename: Louise
authors.initials: L
authors.lastname: Bordeleau
authors.affiliation: Department of Medicine, Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, Ontario, Canada.
authors.forename: Hertzel C
authors.initials: HC
authors.lastname: Gerstein
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D049528:Insulin, Long-Acting / Q000008:administration & dosage*; D009369:Neoplasms / Q000209:etiology*
chemical_list: D000970:Antineoplastic Agents; D015525:Fatty Acids, Omega-3; D007004:Hypoglycemic Agents; D049528:Insulin, Long-Acting